These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33331657)
41. Clinical and pathological investigation of patients with severe COVID-19. Li S; Jiang L; Li X; Lin F; Wang Y; Li B; Jiang T; An W; Liu S; Liu H; Xu P; Zhao L; Zhang L; Mu J; Wang H; Kang J; Li Y; Huang L; Zhu C; Zhao S; Lu J; Ji J; Zhao J JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32427582 [TBL] [Abstract][Full Text] [Related]
42. Elevated Exhaustion Levels of NK and CD8 Li M; Guo W; Dong Y; Wang X; Dai D; Liu X; Wu Y; Li M; Zhang W; Zhou H; Zhang Z; Lin L; Kang Z; Yu T; Tian C; Qin R; Gui Y; Jiang F; Fan H; Heissmeyer V; Sarapultsev A; Wang L; Luo S; Hu D Front Immunol; 2020; 11():580237. PubMed ID: 33154753 [TBL] [Abstract][Full Text] [Related]
43. Prevalence of SARS-CoV-2 in Patients with Severe Pneumonia in Khuzestan Province, Iran. Abolnezhadian F; Makvandi M; Alavi SM; Azaran A; Jalilian S; Rashno M; Kaydani GA; Arshadi M; Hosseinizadeh SM; Boostani H; Seyedian SS; Moogahi S; Salmanzadeh S; Varnaseri M; Neisi N; Keifarrokhi H; Shariati G; Amiri H; Parsanahad M; Nashibi R; Yousefi F; Ahmadi F; AhmadiAngali K Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):471-477. PubMed ID: 33463114 [TBL] [Abstract][Full Text] [Related]
45. IL-6 drives T cell death to participate in lymphopenia in COVID-19. Zhou X; Ye G; Lv Y; Guo Y; Pan X; Li Y; Shen G; He Y; Lei P Int Immunopharmacol; 2022 Oct; 111():109132. PubMed ID: 35964413 [TBL] [Abstract][Full Text] [Related]
46. Autophagy Hijacking in PBMC From COVID-19 Patients Results in Lymphopenia. Barbati C; Celia AI; Colasanti T; Vomero M; Speziali M; Putro E; Buoncuore G; Savino F; Colafrancesco S; Ucci FM; Ciancarella C; Balbinot E; Scarpa S; Natalucci F; Pellegrino G; Ceccarelli F; Spinelli FR; Mastroianni CM; Conti F; Alessandri C Front Immunol; 2022; 13():903498. PubMed ID: 35711451 [TBL] [Abstract][Full Text] [Related]
47. Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients. Pérez-Díez A; Liu X; Calderon S; Bennett A; Lisco A; Kellog A; Galindo F; Memoli MJ; Rocco JM; Epling BP; Laidlaw E; Sneller MC; Manion M; Wortmann GW; Poon R; Kumar P; Sereti I Front Immunol; 2024; 15():1352330. PubMed ID: 38694513 [TBL] [Abstract][Full Text] [Related]
48. Pre-Existing Lymphopenia Increases the Risk of Hospitalization and Death after SARS-CoV-2 Infection. Garbo R; Valent F; Gigli GL; Valente M Infect Dis Rep; 2022 Jan; 14(1):20-25. PubMed ID: 35076526 [TBL] [Abstract][Full Text] [Related]
49. Is lymphopenia different between SARS and COVID-19 patients? Yan S; Wu G FASEB J; 2021 Feb; 35(2):e21245. PubMed ID: 33495994 [TBL] [Abstract][Full Text] [Related]
50. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Adamo S; Chevrier S; Cervia C; Zurbuchen Y; Raeber ME; Yang L; Sivapatham S; Jacobs A; Baechli E; Rudiger A; Stüssi-Helbling M; Huber LC; Schaer DJ; Bodenmiller B; Boyman O; Nilsson J Allergy; 2021 Sep; 76(9):2866-2881. PubMed ID: 33884644 [TBL] [Abstract][Full Text] [Related]
51. Reduction of lymphocyte count at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study. Fei J; Fu L; Li Y; Xiang HX; Xiang Y; Li MD; Liu FF; Xu DX; Zhao H Arch Med Sci; 2023; 19(5):1303-1313. PubMed ID: 37732034 [TBL] [Abstract][Full Text] [Related]
52. Lymphopenia associated with survivin and its downstream pathway in COVID-19 serving as a potential route in COVID-19 pathogenesis. Kahrizi MS; Nasiri K; Ebrahimzadeh F; Yaseri AF; Ghodratizadeh S; Gholamrezaei M; Rahat Dahmardeh A; Adili A; Amjidifar R; Hemmatzadeh M; Arabi M; Maghsoudi MR; Mohammadi H Adv Med Sci; 2024 Mar; 69(1):190-197. PubMed ID: 38521459 [TBL] [Abstract][Full Text] [Related]
53. Value of hematological parameters for predicting patients with severe coronavirus disease 2019: a real-world cohort from Morocco. Azghar A; Bensalah M; Berhili A; Slaoui M; Mouhoub B; El Mezgueldi I; Nassiri O; El Malki J; Maleb A; Seddik R J Int Med Res; 2022 Jul; 50(7):3000605221109381. PubMed ID: 35854474 [TBL] [Abstract][Full Text] [Related]
54. Lymphocyte Levels in Predicting the Outcome of COVID-19 Patient: A Prognostic Study from Single Center in Indonesia. Amin CA; Liana P; Ahmad Z; Hidayat R; Sari NP; Afifah AR; Hilda F J Nepal Health Res Counc; 2021 Dec; 19(3):536-542. PubMed ID: 35140428 [TBL] [Abstract][Full Text] [Related]
56. Investigating the relationship between lymphocyte cells apoptosis and DNA damage and oxidative stress and therapeutic and clinical outcomes of COVID-19 elderly patients. Abiri E; Mirzaii M; Moghbeli M; Atashi A; Harati AA BMC Infect Dis; 2024 Sep; 24(1):940. PubMed ID: 39251946 [TBL] [Abstract][Full Text] [Related]
57. Hematopathology of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Coronavirus Disease-19. Lucas F; Sadigh S Surg Pathol Clin; 2023 Jun; 16(2):197-211. PubMed ID: 37149356 [TBL] [Abstract][Full Text] [Related]
58. The function of myeloid-derived suppressor cells in COVID-19 lymphopenia. Li T; Zheng F; Cheng F Int Immunopharmacol; 2022 Nov; 112():109277. PubMed ID: 36206651 [TBL] [Abstract][Full Text] [Related]
59. Host Response Changes and Their Association with Mortality in COVID-19 Patients with Lymphopenia. Michels EHA; Appelman B; de Brabander J; van Amstel RBE; van Linge CCA; Chouchane O; Reijnders TDY; Schuurman AR; Sulzer TAL; Klarenbeek AM; Douma RA; Bos LDJ; Wiersinga WJ; Peters-Sengers H; van der Poll T; Am J Respir Crit Care Med; 2024 Feb; 209(4):402-416. PubMed ID: 37948687 [No Abstract] [Full Text] [Related]
60. Corona Virus Disease-19 Clinical And Laboratory Characteristics Associated With Disease Severity In Patients Presenting At A Tertiary Care Hospital Of Peshawar. Qayyum W; Khan SA; Saeed L; Jawad M; Khan MF; Ullah I J Ayub Med Coll Abbottabad; 2021; 33(3):507-512. PubMed ID: 34487667 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]